NCT05999994 2026-03-27
CAMPFIRE
Eli Lilly and Company
Phase 2 Recruiting
Clinical Trials
10 trialsNCT06107413 2025-12-12
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
AbbVie
Phase 2 Active not recruiting
NCT03806309 2025-07-25
TEDOPAM
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Active not recruiting
NCT05217069 2025-04-16
FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC
Ludwig-Maximilians - University of Munich
Phase 2 Completed
NCT02178709 2022-04-19
A Phase II Study of Neoadjuvant FOLFIRINOX
Indiana University
Phase 2 Completed
NCT01660711 2021-11-08
A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma
Endeavor Health
Phase 2 Completed
NCT02241551 2018-07-26
Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer
University of Pittsburgh
Phase 2 Terminated
NCT02316496 2017-08-01
REGAIN
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Terminated
NCT00066781 2017-04-04
Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00057473 2011-04-14
A Phase II Study of Carboplatin Plus Irinotecan Versus Irinotecan in Children With Refractory Solid Tumors
Bristol-Myers Squibb
Phase 2 Completed